Australian gold assay technology company Chrysos Corporation has increased its debt financing headroom by A$105 million and put funding in place “to accelerate growth”.
The ASX-listed company said a new three-year, $200m syndicated facility with domestic financiers ANZ, National Australia Bank and Export Finance Australia provided additional capital to support manufacturing and deployments of its PhotonAssay units “as global adoption … continues to grow”.
“The funding supports Chrysos’ return to its target manufacturing cadence of 18 units per year, with the forward order book now extending to a further 22 PhotonAssay units and 27 long-lead components, positioning the company for anticipated growth through FY27 and beyond,” Chrysos said.
The company said last month deployed PhotonAssay units processed one million samples in March and April, underscoring rising global use and productivity. Its alternative method of analysing gold and other mineral samples, replacing conventional fire assaying, was being used by a number of large miners, contractors and mineral testing groups.
Chrysos is targeting fiscal year 2026 revenue of $80-90 million and $20-27 million EBITDA. It said sample volumes underpinned higher utilisation and additional assay charges, or AAC, “a key revenue and profitability driver”.
The company’s share price is well down on its March 2026 high of $10.13 at $6, capitalising it at $695 million.
